Exactly, and I am not certain but believe the FDA late approval on juveniles (which is where more of the $$ is at) will give them better shot at another extension past the 2027, but, the first is a shoe in (2027)
IMHO when juvenile comes through and the BARDA contract kicks in with it, is when this little pony gets bought and taken to another pasture, JMHO. Then it is the big boys problem which they (big pharma) have ways of getting that sorted, lobbyists etc.
Peace out.
News 
Market Data 
Discover 
